Author’s response to reviews

Title: Effect of dabrafenib on melanoma cell lines harboring the BRAFV600D/R mutations

Authors:

Giusy Gentilcore (giusy.gentilcore@gmail.com)
Gabriele Madonna (gabriele.madonna@yahoo.it)
Nicola Mozzillo (nimozzi@tin.it)
Antoni Ribas (aribas@mednet.ucla.edu)
Giuseppe Palmieri (gpalmieri@yahoo.com)
Paolo A Ascierto (paolo.ascierto@gmail.com)

Version: 2 Date: 21 May 2012

Dear Editor in Chief,

I am writing to you as the corresponding author of the attached manuscript entitled “Effect of dabrafenib on melanoma cell lines harboring the BRAFV600D/R mutations” by Gentilcore et al., to be considered for publication in BMC Cancer as Research Article.

All authors of this non research paper have participated in its drafting. All authors have read and approved the final version of the manuscript as well as agreed about its submission to the BMC Cancer. The contents of this manuscript: a) have not been copyrighted or published previously; b) are not now under consideration for publication elsewhere; c) will not be copyrighted, submitted, or published elsewhere while acceptance by the Journal is under consideration.

Recently, the BRAF inhibitors (vemurafenib/dabrafenib) showed an efficacy in the treatment of advanced melanoma patients harboring the V600E/KBRAF mutation. Our manuscript is the first to demonstrate activity of dabrafenib also against V600D/RBRAF mutated cell lines derived from patients.

We hope you will agree that this manuscript merits publication in BMC Cancer.

We look forward to hearing from you in due course.

Yours sincerely,

Paolo A. Ascierto, MD
Unit of Medical Oncology and Innovative Therapy
Istituto Nazionale Tumori Fondazione "G. Pascale"
Via Mariano Semmola
80131 Napoli - Italy
Tel/Fax +39 081 5903841
Mobile +39 338 740 2333
email: paolo.ascierto@gmail.com